Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Dysregulation of astrocytic DNAJC6 contributes to sporadic Parkinson’s disease pathogenesis
Wahyu Handoko Wibowo Darsono, Yeongran Hwang, Erica Valencia, Leonardo Tejo Gunawan, Seung Jae Hyeon, Hoon Ryu, Thor D. Stein, Mi-Yoon Chang, Noviana Wulansari, Sang-Hun Lee
Wahyu Handoko Wibowo Darsono, Yeongran Hwang, Erica Valencia, Leonardo Tejo Gunawan, Seung Jae Hyeon, Hoon Ryu, Thor D. Stein, Mi-Yoon Chang, Noviana Wulansari, Sang-Hun Lee
View: Text | PDF
Research Article Clinical Research Neuroscience

Dysregulation of astrocytic DNAJC6 contributes to sporadic Parkinson’s disease pathogenesis

  • Text
  • PDF
Abstract

Loss-of-function mutations in DNAJC6, encoding the cochaperone auxilin (HSP40 family), cause familial juvenile-onset Parkinson’s disease (PD). Given the chaperone role of DNAJC6 in cellular homeostasis in adult neurons, we hypothesized that DNAJC6 dysfunction may not be limited to juvenile-onset disorders but could also be associated with adult-onset brain diseases. Here, we show that DNAJC6 expression is significantly downregulated in postmortem substantia nigra tissues and transcriptomic datasets from patients with late-onset sporadic PD. Consistently, human pluripotent stem cell–derived midbrain cultures exhibited reduced DNAJC6 expression under multiple PD-associated conditions. Mechanistically, DNAJC6 loss resulted from impaired transcription mediated by the midbrain-specific factors NURR1/FOXA2 and reduced protein stability regulated by LRRK2. Beyond neurons, DNAJC6 was robustly expressed in astrocytes and similarly downregulated in sporadic PD contexts. Astrocytic DNAJC6 deficiency impaired phagocytic, autolysosomal, and mitochondrial functions while promoting a proinflammatory phenotype, thereby exacerbating neurodegenerative pathology. Importantly, epigenetic restoration of DNAJC6 in neurons and astrocytes using a CRISPRa-AAV9 system in the substantia nigra of an α-synuclein–induced PD mouse model alleviated behavioral deficits and neuropathology. These findings provide evidence that DNAJC6 dysregulation is associated with pathogenic processes in sporadic PD and suggest that targeting neuronal and astrocytic DNAJC6 could represent a potential disease-modifying strategy.

Authors

Wahyu Handoko Wibowo Darsono, Yeongran Hwang, Erica Valencia, Leonardo Tejo Gunawan, Seung Jae Hyeon, Hoon Ryu, Thor D. Stein, Mi-Yoon Chang, Noviana Wulansari, Sang-Hun Lee

×

Figure 1

Downregulation of DNAJC6 expression in sporadic PD contexts.

Options: View larger image (or click on image) Download as PowerPoint
Downregulation of DNAJC6 expression in sporadic PD contexts.
(A) Scatter...
(A) Scatterplot showing up- and downregulated genes in the transcriptomes of postmortem brains (Brodmann area 9 [BA9]) from 29 patients with sporadic PD versus 44 acting as controls (GSE68719). (B) Heatmap illustrating gene expression profiles of interest, highlighting the downregulation of DNAJC6 in PD patients’ brains compared with controls (GSE68719). (C) DNAJC6 expression levels across multiple transcriptomic datasets from sporadic PD brains and PD patient–derived cells harboring PD-associated gene variants (GBA, SNCA, and LRRK2). Data are presented as log2 FC of DNAJC6 expression in PD versus controls, with statistical significance indicated by P values. (D) Protein levels of DNAJC6 in the midbrain SN and ventral tegmental area (VTA) of patients with sporadic PD (sPD) compared with age-matched controls. Original magnification, ×1. A total of 30 cells were counted (10 cells/case; control, N = 3; PD patient, N = 3); **P < 0.01; nested 2-tailed t test. (E–G) Downregulation of DNAJC6 under various in vitro conditions mimicking sporadic PD contexts. Human midbrain neuron/astrocyte cultures (derived from hESCs, H9) were exposed to PD-associated toxins, including α-syn PFFs (2 μg/mL), H2O2 (200 μM), LPS (1 μg/mL), TNF-α (20 ng/mL), rotenone (100 nM), and menadione (20 μM) for 48 h before analysis. α-Syn pathology was assessed by percent pS129-α-syn+/TH+ cells (F, lower panel). α-Syn PFF treatment was applied under in vitro conditions mimicking sporadic PD (E and F; detailed analysis is shown in Supplemental Figure 12). Scale bars in F: 25 μm (top), 50 μm (bottom). (H and I) Analysis of human midbrain cultures derived from PD-iPSCs carrying LRRK2 variants (and WT iPSCs). DNAJC6 expression was assessed via qPCR (E), MFI in ICC (F), and WB (G–I) analyses. n = 3~4 independent experiments (E and G–I), n = 12 (F, % DNAJC6 intensity) or 8 (F, % p-S129 α-syn) independent cultures; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; unpaired 2-tailed t test (E and F) or 1-way ANOVA followed by Dunnett’s test (G–I).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts